Navigation Links
GeneTex Introduces New Mouse Monoclonal Antibody Against the Ten-Eleven Translocation 1 (TET1) Protein for DNA Methylation/Epigenetics Research

IRVINE, Calif., May 8, 2013 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies and antibody-related reagents, is introducing a new mouse monoclonal antibody to the human Ten-Eleven Translocation 1 (TET1) protein. The discovery in 2009 (Tahiliani et al, 2009) that this enzyme can convert the DNA methylation mark 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) helped to usher in a new field of research in epigenetics.  Since then, it has become clear that TET1 and its family members TET2 and TET3, through the oxidation of 5mC to 5hmC, 5-formylcytosine (5fC), or 5-carboxylcytosine (5caC), are pivotal factors in epigenetic signaling.


The excitement generated by the mammalian TET proteins in the last few years is due to their impact on the regulation of DNA methylation, a fundamental epigenetic mechanism that generally causes genes to be turned off through direct methylation of particular cytosines (5mC) in the DNA sequence. The enzymes responsible for this DNA methylation, termed DNA methyltransferases (DNMTs), have been identified and characterized. However, how DNA could be actively demethylated remained a puzzle. It is now thought that the TET enzymes are intimately involved in this process through the conversion of 5mC to 5hmC, 5fC, and 5caC, essentially forming a stepwise pathway to demethylation. Thus, the actions of these enzymes facilitate dynamic regulation of DNA methylation, with the readily apparent implications for development and carcinogenesis.  Even more intriguing to epigenetics researchers, however, is the growing appreciation that these 5mC derivatives, in particular 5hmC, are epigenetic signals in their own right.

TET1 is known to be a challenging protein to develop quality antibodies against and GeneTex is pleased to announce a first to market mouse monoclonal TET1 antibody [GT1462] (GTX627420) that is the most extensively characterized commercially available TET1 antibody.  Qualitative validation has demonstrated that this antibody can detect the human TET1 protein in ICC/IF, IHC-P, and western blot applications.  Importantly, its specificity was verified by both overexpression and siRNA studies. GeneTex also produces polyclonal antibodies against TET1 as well as additional antibodies to TET2, TET3, and 5mC. For more information on GeneTex, Inc. and its products, please call toll-free 877-GENETEX (436-3839) or visit

About GeneTex, Inc.

GeneTex, Inc. is an antibody manufacturing company founded in 1997 by a group of internationally renowned academic scientists. They strive to produce the highest quality antibodies and reagents. Their primary and secondary antibodies are created through a process involving extensive research, development, and validation. GeneTex's catalog has grown to over 55,000 primary antibodies and supportive reagents, which are all backed with a 100% Satisfaction Guarantee.

Corporate Mission

We strive to serve and accelerate life science research by creating essential life science tools where quality can be found in every vial.

SOURCE GeneTex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
2. GeneTex, Inc. to Attend the 2012 Annual Meeting of the American Society for Cell Biology
3. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
4. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
5. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
6. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
7. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
8. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
9. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
10. JPSA Introduces Picosecond Laser Micromachining System
11. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
Post Your Comments:
(Date:11/30/2015)... 30, 2015  Champions Oncology, Inc. (CSBR), engaged in ... personalize the development and use of oncology drugs, today ... will be presenting at the LD MICRO Investor Conference ... Time (PST).  The conference, held at the Luxe Sunset ... , will feature 200 small/micro-cap companies and is ...
(Date:11/30/2015)... JACKSONVILLE, Florida , November 30, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, today announced it will be presenting ... Event on December 1, 2015 at 2.30 PM PT. ... member and Strategic Advisor will be giving the presentation ...
(Date:11/30/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty healthcare ... at two upcoming investor conferences. Aytu is scheduled to ... to be held December 3, 2015, and at LD ... 2 nd & 3 rd , 2015 in ... via webcast. Josh Disbrow , Chief Executive ...
(Date:11/30/2015)... Florida and MAGDEBURG, Germany , ... of NeuroRehabilitation (ECNR) in Vienna, Austria ... 3rd European Congress of NeuroRehabilitation (ECNR) in ... --> NovaVision, a wholly owned subsidiary of Vycor ... European version of its Internet-delivered NovaVision Therapy Suite at the ...
Breaking Biology Technology:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... -- Vigilant Solutions announces today that Mr. Dick W. ... --> --> Mr. Boyce ... at TPG Capital, one of the largest global investment ... revenue.  He founded and led TPG,s Operating Group, which ... 1997 to 2013.  In his first role, he served ...
Breaking Biology News(10 mins):